<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="80b57cfe-7819-4d95-a57d-014af42f118d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BLUJEPA safely and effectively. See full prescribing information for BLUJEPA.<br/>
      <br/>BLUJEPA (gepotidacin) tablets, for oral use<br/>Initial U.S. Approval: 2025</title>
   <effectiveTime value="20250325"/>
   <setId root="80b57cfe-7819-4d95-a57d-014af42f118d"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="167380711" root="1.3.6.1.4.1.519.1"/>
            <name>GlaxoSmithKline LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="a84b495b-0731-4d17-b5fa-ec94878d528c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="0173-0922"/>
                        <name>Blujepa</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>gepotidacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="750"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5P7X0H2O6B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GEPOTIDACIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="DVF0PR037D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GEPOTIDACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0922-45" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250325"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA218230" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20250325"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250325"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">G5;GU3</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_ced5ab1e-5364-4f0d-970e-fc4296307f62">
               <id root="4c1faa56-ebe6-4cd4-9968-f4022813c75c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii </content>complex<content styleCode="italics">, Staphylococcus saprophyticus, </content>and<content styleCode="italics"> Enterococcus faecalis</content>. (<linkHtml href="#ID_66283b99-13a9-49e2-b6de-60d28c28c020">1.1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Usage to Reduce Development of Drug-Resistant Bacteria</content>
                        </paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#ID_0398c289-3dc8-4763-8577-a21f8cb8ef5b">1.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_66283b99-13a9-49e2-b6de-60d28c28c020">
                     <id root="f333c32d-322b-44e6-9577-7871671015a1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Treatment of Uncomplicated Urinary Tract Infections </title>
                     <text>
                        <paragraph>BLUJEPA is indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: <content styleCode="italics">Escherichia coli</content>, <content styleCode="italics">Klebsiella pneumoniae</content>,<content styleCode="italics"> Citrobacter freundii </content>complex,<content styleCode="italics"> Staphylococcus saprophyticus</content>, and<content styleCode="italics"> Enterococcus faecalis</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0398c289-3dc8-4763-8577-a21f8cb8ef5b">
                     <id root="c441d67f-b3fa-48ce-a929-3f5961a41db7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Usage to Reduce Development of Drug-Resistant Bacteria </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9eed69cf-15d1-4df1-817d-f1bbde50da5f">
               <id root="3789807f-e06b-4e85-ae14-cc27475f4dc9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The recommended dosage of BLUJEPA is 1,500 mg (two 750 mg tablets) taken orally, twice daily (approximately 12 hours apart), for 5 days. (<linkHtml href="#ID_8b94f772-a22d-433c-8535-699f0731f059">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer BLUJEPA tablets after a meal to reduce the possibility of gastrointestinal intolerance. (<linkHtml href="#ID_8b94f772-a22d-433c-8535-699f0731f059">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8b94f772-a22d-433c-8535-699f0731f059">
                     <id root="911e3fb8-6e3e-4271-a61d-9a98d28fbd3b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage for Female Adult and Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg </title>
                     <text>
                        <paragraph>The recommended dosage of BLUJEPA is 1,500 mg (two 750 mg tablets) taken orally, twice daily (approximately 12 hours apart) for 5 days. Administer BLUJEPA tablets after a meal to reduce the possibility of gastrointestinal intolerance <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2c4b5b95-05bd-4dc3-a5fb-d72a227eda95">
                     <id root="8ddec627-7dcf-4ddf-be01-2e3f8828845e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommendations Regarding Missed Dose(s)</title>
                     <text>
                        <paragraph>If a dose is missed, instruct patients to take the missed dose as soon as possible. Do <content styleCode="bold">
                              <content styleCode="underline">not</content>
                           </content> double the dose to make up for a missed dose.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5a790472-eeb5-469d-af81-2822d94205d8">
               <id root="64e8737a-07db-44c9-b54b-2ce72030de6f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Each film coated tablet of BLUJEPA contains 750 mg of gepotidacin. BLUJEPA tablets are yellow, capsule shaped, and debossed with “GS GU3” on one side and plain on the other side.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 750 mg of gepotidacin. (<linkHtml href="#ID_5a790472-eeb5-469d-af81-2822d94205d8">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_63b0cc82-8128-4ba2-ba1b-f15bcbed2400">
               <id root="91d1c430-70ca-410f-b6bf-e0ce434b917a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>BLUJEPA is contraindicated in patients with a history of severe hypersensitivity to BLUJEPA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_5d00828f-b4fe-4da0-97de-23a789ad672f">5.3</linkHtml>), and Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>A history of severe hypersensitivity to BLUJEPA. (<linkHtml href="#ID_63b0cc82-8128-4ba2-ba1b-f15bcbed2400">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_7fa92173-5484-4ea7-a48b-84edb134e308">
               <id root="56ab6ac6-2498-4d10-9d16-9472d986daaa"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>QTc Prolongation: Avoid use of BLUJEPA in patients with a history of QTc prolongation, or with relevant pre-existing cardiac disease, and in patients receiving drugs that prolong the QTc interval. Due to an increase in BLUJEPA exposure, avoid concomitant administration of BLUJEPA with strong CYP3A4 inhibitors and in patients with severe hepatic impairment (Child-Pugh Class C) and in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;30 mL/min). (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Acetylcholinesterase inhibition: Dysarthria and other adverse reactions have been reported in patients receiving BLUJEPA. Monitor patients with underlying medical conditions that may be exacerbated by acetylcholinesterase inhibition and patients receiving succinylcholine-type neuromuscular blocking agents, systemic anticholinergic medications, or non-depolarizing neuromuscular blocking agents. (<linkHtml href="#ID_ac8a806c-4ede-4931-a814-cc2f1790195d">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving BLUJEPA. If an allergic reaction to BLUJEPA occurs, discontinue the drug and institute appropriate supportive measures. (<linkHtml href="#ID_5d00828f-b4fe-4da0-97de-23a789ad672f">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Clostridioides difficile Infection</content> (CDI): CDI has been reported with nearly all systemic antibacterial agents, including BLUJEPA. Evaluate patients who develop diarrhea. (<linkHtml href="#ID_ad8b4566-6229-492b-b1e7-a66d456566ed">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">
                     <id root="a49a5002-bb28-4c38-8209-c642adbe71cf"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 QTc Prolongation</title>
                     <text>
                        <paragraph>A dose and concentration-dependent prolongation of the QTc interval has been observed with BLUJEPA <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_345d3108-5a4c-40a5-8e00-e8550675d5fc">12.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Avoid BLUJEPA in patients with a history of QTc interval prolongation or those with relevant pre‑existing cardiac disease, patients taking antiarrhythmic agents, or other medications that may potentially prolong the QTc interval <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_19874d09-77e7-45ff-a9ed-24099053dbfe">7.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Due to an increase in gepotidacin exposure (C<sub>max</sub>) and the risk of QTc interval prolongation, avoid concomitant administration of BLUJEPA with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole), in patients with severe hepatic impairment (Child‑Pugh Class C), or in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;30 mL/min) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_084554e9-1731-4e83-a89c-9a64e3908c96">7.1</linkHtml>), and Use in Specific Populations (<linkHtml href="#ID_db5c9302-bc72-4e10-b354-f03daaef33ed">8.6</linkHtml>, <linkHtml href="#ID_3f8d7286-61e4-480c-b336-753162a98f58">8.7</linkHtml>)]</content>.</paragraph>
                        <paragraph>If administration of BLUJEPA cannot be avoided in these patients, monitor and correct serum electrolyte abnormalities and collect an ECG prior to administration and during treatment, as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ac8a806c-4ede-4931-a814-cc2f1790195d">
                     <id root="7518c3f2-d78c-4ade-bd08-1dca9162d8f1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Acetylcholinesterase Inhibition</title>
                     <text>
                        <paragraph>BLUJEPA is a reversible acetylcholinesterase inhibitor in in vitro laboratory studies. Adverse reactions including dysarthria, presyncope, muscle spasms, diarrhea, nausea, vomiting, abdominal pain, hypersalivation, and hyperhidrosis which are potentially attributed to acetylcholinesterase inhibition, have been observed in clinical trials <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)]</content>. Increased cholinergic effects can be associated with severe adverse reactions including atrioventricular block, bradycardia, bronchospasm, seizures/convulsions, and vasovagal syncope. Monitor patients with medical conditions that may be exacerbated by acetylcholinesterase inhibition.</paragraph>
                        <paragraph>BLUJEPA, as an acetylcholinesterase inhibitor, may exaggerate the neuromuscular effects of succinylcholine‑type muscle relaxation during anesthesia. BLUJEPA may exaggerate the effects of other acetylcholinesterase inhibitors. Monitor patients for exaggerated neuromuscular blockade or excessive cholinergic effects.</paragraph>
                        <paragraph>Because BLUJEPA may antagonize the effects of systemic anticholinergic medications or non‑depolarizing neuromuscular blocking agents, monitor patients if BLUJEPA is concomitantly administered with these medications <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_86f6685b-3186-44a9-b7ea-70717dd0fa96">7.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5d00828f-b4fe-4da0-97de-23a789ad672f">
                     <id root="79f35030-99e3-4ce2-ba38-b3a2014d8551"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving BLUJEPA <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)]</content>. BLUJEPA is contraindicated in patients with a history of severe hypersensitivity to BLUJEPA <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_63b0cc82-8128-4ba2-ba1b-f15bcbed2400">4</linkHtml>)].</content> Before therapy with BLUJEPA is instituted, carefully inquire about previous hypersensitivity reactions to BLUJEPA. If an allergic reaction to BLUJEPA occurs, discontinue the drug and institute appropriate supportive measures.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ad8b4566-6229-492b-b1e7-a66d456566ed">
                     <id root="e61f511a-a6c5-4285-8f68-512774e6ed7f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 <content styleCode="italics">Clostridioides difficile</content> Infection</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile (C. difficile)</content> infection (CDI) has been reported for nearly all systemic antibacterial agents, including BLUJEPA, and may range in severity from mild diarrhea to fatal colitis <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_6221d462-6ee1-4c65-9ca0-c01a5b81ad43">6</linkHtml>)]</content>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDI. Hypertoxin producing isolates of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDI must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDI has been reported to occur over 2 months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDI is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04171f7f-dfc2-4fe3-9b2d-b1ff6bf0a92b">
                     <id root="289b84b3-9ee7-4f62-9a77-b0c8bd71d67f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Development of Drug-Resistant Bacteria </title>
                     <text>
                        <paragraph>Prescribing BLUJEPA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_0398c289-3dc8-4763-8577-a21f8cb8ef5b">1.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6221d462-6ee1-4c65-9ca0-c01a5b81ad43">
               <id root="71f5e04e-ebc6-4ae4-94b7-c154747f66e7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>QTc Prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Acetylcholinesterase Inhibition <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ac8a806c-4ede-4931-a814-cc2f1790195d">5.2</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_5d00828f-b4fe-4da0-97de-23a789ad672f">5.3</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>Clostridioides difficile Infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ad8b4566-6229-492b-b1e7-a66d456566ed">5.4</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions occurring in ≥1% of patients are diarrhea, nausea, abdominal pain, flatulence, headache, soft feces, dizziness, vomiting, and vulvovaginal candidiasis. (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1466cc64-2af5-4062-962b-af80d9e9d144">
                     <id root="7ceb9fd1-79d2-4960-b764-d50c948c53c9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of BLUJEPA was evaluated in 2 double‑blind, active‑controlled, randomized trials in female adult and pediatric patients 12 years of age and older with uUTI (Trial 1 and Trial 2). A total of 1,570 patients were treated with BLUJEPA and 1,558 patients were treated with nitrofurantoin (pooled safety populations for BLUJEPA and nitrofurantoin, respectively). Patients received treatment for a median duration of 5 days.</paragraph>
                        <paragraph>In Trials 1 and 2 (pooled, intent-to-treat [ITT] population), the median age of patients treated with BLUJEPA was 49 (range 13 to 89) years; &lt;1% were &lt;18 years, 77% of patients were 18 to 64 years, 14% were 65 to 74 years, and 8% were ≥75 years. Patients were female (100%) and White (83%), Black or African American (7%), Asian (5%), or American Indian or Alaskan Native (4%); for ethnicity, 33% identified as Hispanic/Latino and 67% as non-Hispanic/Latino. The majority of patients were enrolled from the U.S. (55%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation</content>
                        </paragraph>
                        <paragraph>In the pooled trials (Trials 1 and 2), serious adverse reactions occurred in 1/1,570 (&lt;1%) patient treated with BLUJEPA and 1/1,558 (&lt;1%) patient treated with nitrofurantoin. The serious adverse reaction reported with BLUJEPA was dysarthria. No adverse reaction led to death in either treatment group.</paragraph>
                        <paragraph>In the pooled trials, adverse reactions leading to discontinuation of treatment occurred in 79/1,570 (5%) of patients treated with BLUJEPA and 30/1,558 (2%) of patients treated with nitrofurantoin. Adverse reactions occurring in &gt;1% of patients leading to treatment discontinuation in patients treated with BLUJEPA included diarrhea (3%) and nausea (1%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <linkHtml href="#_Ref192844993">Table 1</linkHtml> lists the adverse reactions occurring in ≥1% of patients receiving BLUJEPA in the pooled trials (Trials 1 and 2).</paragraph>
                        <table ID="_Ref192844993" width="100%">
                           <caption>Table 1. Adverse Reactions Occurring in ≥1% of Uncomplicated Urinary Tract Infection Patients Treated with BLUJEPA (Trials 1 and 2 Pooled Data; Safety Population)</caption>
                           <col width="31%"/>
                           <col width="36%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">
                                    <sup>a</sup> Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal tenderness, abdominal discomfort, and gastrointestinal pain.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">BLUJEPA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 1,570</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Nitrofurantoin</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N = 1,558</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>258 (16)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>51 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>146 (9)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>64 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Abdominal pain<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>60 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>34 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Flatulence</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>43 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>8 (&lt;1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>38 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>40 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Soft feces</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>37 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>8 (&lt;1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>29 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>19 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>28 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>10 (&lt;1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>Vulvovaginal candidiasis</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>20 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>18 (1)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Diarrhea:</content> In Trial 1 and 2, diarrhea was reported in 258/1,570 (16%) patients receiving BLUJEPA; 11% mild, 5% moderate, and &lt;1% severe. The diarrhea started within the first 2 days of treatment for the majority of patients and the median duration of diarrhea was 4 days.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Occurring in Less than 1% of Patients Receiving BLUJEPA in Trials 1 and 2 (pooled):</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Abdominal distension, dyspepsia (includes epigastric discomfort, eructation)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Presyncope, dysarthria</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and Infestations: Clostridioides difficile</content> infection</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Muscle spasms</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content> Hot flush</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders:</content> Tachycardia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Blurred vision</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders:</content> Vertigo</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Disorders:</content> Fatigue</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> Alanine aminotransferase/aspartate aminotransferase increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue:</content> Rash, hyperhidrosis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> Hypersensitivity reactions</paragraph>
                        <paragraph>
                           <content styleCode="underline">Select Adverse Reactions Occurring in Patients Receiving BLUJEPA in Phase 1 and 2 Clinical Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> hypersalivation (with oral daily doses ranging from 100 mg to 6,000 mg, which includes not approved doses)</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_24072bad-2512-4604-b60d-ca5843457673">
               <id root="b10274c8-db14-4812-a3e8-daf857eaff48"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>CYP3A4 Inhibitors: Avoid coadministration of BLUJEPA with strong CYP3A4 inhibitors. (<linkHtml href="#ID_084554e9-1731-4e83-a89c-9a64e3908c96">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>CYP3A4 Inducers: Avoid coadministration of BLUJEPA with strong CYP3A4 inducers (<linkHtml href="#ID_084554e9-1731-4e83-a89c-9a64e3908c96">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>CYP3A4 Substrates: Avoid coadministration of BLUJEPA with drugs that are extensively metabolized by CYP3A4 and have a narrow therapeutic window. (<linkHtml href="#ID_2654249c-224d-441b-bd81-76029c98c689">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (<linkHtml href="#ID_2654249c-224d-441b-bd81-76029c98c689">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_084554e9-1731-4e83-a89c-9a64e3908c96">
                     <id root="5bcba0c1-4913-40a0-81ad-b5fbcff43b96"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on BLUJEPA</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CYP3A4 Inhibitors</content>
                        </paragraph>
                        <paragraph>Due to an increase in gepotidacin exposures, avoid concomitant administration of BLUJEPA with strong inhibitors of CYP3A4 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">CYP3A4 Inducers</content>
                        </paragraph>
                        <paragraph>Due to a decrease in gepotidacin exposures, avoid concomitant administration of BLUJEPA with strong inducers of CYP3A4 <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2654249c-224d-441b-bd81-76029c98c689">
                     <id root="bbfe7c09-6eaf-4714-9937-42e77bbb0f9d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of BLUJEPA on Other Drugs </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">CYP3A4 Substrates</content>
                        </paragraph>
                        <paragraph>Avoid concomitant administration of BLUJEPA with drugs that are extensively metabolized by CYP3A4 and have a narrow therapeutic index (e.g., quinidine, cyclosporine) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Digoxin</content>
                        </paragraph>
                        <paragraph>Due to an increase in digoxin exposures, consider monitoring digoxin serum concentrations, as appropriate, with concomitant administration of BLUJEPA <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_86f6685b-3186-44a9-b7ea-70717dd0fa96">
                     <id root="1c119d0e-6f26-4da8-8138-906402ae3409"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Cholinergic/Anticholinergic Drugs</title>
                     <text>
                        <paragraph>As gepotidacin is an acetylcholinesterase inhibitor, there is potential for an exaggerated effect of concomitantly administered succinylcholine‑type neuromuscular blocking agents resulting in a delay in recovery of neuromuscular function. Gepotidacin may augment the effect of other acetylcholinesterase inhibitors (e.g., donepezil). Monitor for exaggerated neuromuscular blockade or excessive cholinergic effects <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ac8a806c-4ede-4931-a814-cc2f1790195d">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>There is potential for an antagonistic effect with systemic anticholinergic medications (e.g., benztropine, oxybutynin) or non‑depolarizing neuromuscular blocking agents. Consider the potential for this interaction if BLUJEPA is administered concomitantly with anticholinergic medications <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ac8a806c-4ede-4931-a814-cc2f1790195d">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_19874d09-77e7-45ff-a9ed-24099053dbfe">
                     <id root="7693f7a0-46f0-45a6-8155-0f7e49cdbc6b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs that Prolong the QTc Interval</title>
                     <text>
                        <paragraph>Due to the increased risk of QTc prolongation, avoid concomitant administration of BLUJEPA with other medications that have the potential to prolong the QTc interval <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_85657ab3-b8cb-4a54-af4e-a6b25447e8f7">
               <id root="fe02b8d6-ad61-40a7-955b-c708f19e83e6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Renal Impairment: Avoid use of BLUJEPA in patients with severe renal impairment with eGFR &lt;30 mL/min, including those receiving dialysis. (<linkHtml href="#ID_db5c9302-bc72-4e10-b354-f03daaef33ed">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatic Impairment: Avoid use of BLUJEPA in patients with severe hepatic impairment (Child-Pugh Class C). (<linkHtml href="#ID_3f8d7286-61e4-480c-b336-753162a98f58">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6e972305-6fe3-41a2-982e-9aea127d17d6">
                     <id root="0b49a1d0-c300-4c7b-9909-60e596856c34"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>A pregnancy exposure registry will be established to monitor pregnancy outcomes in women exposed to BLUJEPA during pregnancy. Pregnant women exposed to BLUJEPA, and healthcare providers are encouraged to contact GlaxoSmithKline at 1‑888‑825‑5249.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on the use of BLUJEPA in pregnant women to evaluate for a drug‑associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes.</paragraph>
                        <paragraph>In embryo‑fetal development studies in mice and rats, decreased fetal weights and increased fetal mortality (late resorptions) were observed at exposures about 0.8-to-1-times the maximum recommended human dose (MRHD). In a mouse pre- and postnatal development study, there were no adverse developmental effects at exposures of approximately 3-times the MRHD <content styleCode="italics">(see <linkHtml href="#_RefData">Data</linkHtml>)</content>.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage, in clinically recognized pregnancies, is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph ID="_RefData">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data:</content> Gepotidacin did not cause malformations when orally administered in embryo‑fetal development studies during organogenesis. Decreased fetal weights were seen in rats dosed orally with 450 mg/kg/day or greater (approximately equal to the MRHD based on AUC extrapolated from nonpregnant rats) and decreased fetal weights and increased late fetal resorptions were seen in mice at oral doses 500 mg/kg/day or greater (approximately 0.8-times the MRHD based on AUC extrapolated from nonpregnant mice).</paragraph>
                        <paragraph>In a pre- and post‑natal development study in mice given oral doses of up to 1,000 mg/kg/day (approximately 3‑times the MRHD), there were no gepotidacin effects on parturition, or post‑natal growth and development of the offspring.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_64a619e1-cb78-41fb-8df5-4f152c74381f">
                     <id root="6591a985-5517-4ef6-a3fc-1729426ed4f9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of gepotidacin in human milk, its effects on the breastfed child, or on milk production. Based on a study in lactating mice, gepotidacin is likely transferred into milk <content styleCode="italics">(see <linkHtml href="#_RefData_Lactation">Data</linkHtml>).</content> When a drug is present in animal milk, it is likely that the drug will be present in human milk.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BLUJEPA and any potential adverse effects on the breastfed child from BLUJEPA or from the underlying maternal condition.</paragraph>
                        <paragraph ID="_RefData_Lactation">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Gepotidacin concentrations in milk have not been measured directly in animals. However, in a pre- and post‑natal development study when gepotidacin was orally administered to maternal mice during pregnancy and lactation, at all tested doses, gepotidacin was detected in the plasma of their nursing offspring (with dosing 200 mg/kg/day or greater, which was expected to result in exposures 0.5-times the MHRD and higher as extrapolated from exposures in nonpregnant mice).</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9ba66cd4-ee13-4b5d-806b-6ecc2fa670d6">
                     <id root="a6f5641b-61e5-44dc-a501-6077c2fef2c5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of BLUJEPA for the treatment of uUTI have been established in female pediatric patients 12 years of age and older, weighing at least 40 kg. Use of BLUJEPA in these patients is supported by evidence from adequate and well‑controlled studies of BLUJEPA in female adult and pediatric patients 12 years of age and older with uUTI and additional pharmacokinetic data in pediatric patients (12 to &lt;18 years of age) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>), and Clinical Studies (<linkHtml href="#ID_c5a40d9e-9aca-4203-ae71-14f99b2967e3">14.1</linkHtml>)]</content>. The safety profile of BLUJEPA in female pediatric patients 12 years of age and older was similar to female adults with uUTI treated with BLUJEPA <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>), and Clinical Studies (<linkHtml href="#ID_c5a40d9e-9aca-4203-ae71-14f99b2967e3">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of BLUJEPA have not been established in pediatric patients less than 12 years of age or weighing less than 40 kg.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_62dd13e6-a3df-44a4-9836-6dd76931b082">
                     <id root="acee507d-84d9-46a8-859b-8e39d720ef06"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the total number of patients who received treatment with BLUJEPA in the uUTI studies (Trials 1 and 2), 226 (14%) were 65 to less than 75 years of age and 127 (8%) were 75 years of age and older <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_c5a40d9e-9aca-4203-ae71-14f99b2967e3">14.1</linkHtml>)]</content>. No overall differences in safety or effectiveness of BLUJEPA were observed between patients 65 years of age and older and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>BLUJEPA is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_db5c9302-bc72-4e10-b354-f03daaef33ed">8.6</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_db5c9302-bc72-4e10-b354-f03daaef33ed">
                     <id root="393dc5a6-9b52-4d79-96d4-ce90e951cd76"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88828-9" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is required in patients with mild renal impairment (eGFR 60 to 89 mL/min) or moderate renal impairment (eGFR 30 to 59 mL/min). Avoid use of BLUJEPA in patients with severe renal impairment or kidney failure (eGFR &lt;30 mL/min), including those receiving dialysis, due to increased exposure to gepotidacin and the risk of QTc prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3f8d7286-61e4-480c-b336-753162a98f58">
                     <id root="3292f392-3980-4b05-918e-ab5d9743cdaa"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child‑Pugh Class A/B). Avoid use of BLUJEPA in patients with severe hepatic impairment (Child‑Pugh Class C) due to increased exposure to gepotidacin and the risk of QTc prolongation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2f7e74ec-a4fa-465d-9a75-7f1efb96ad3b">
               <id root="6886a236-020b-4cf9-918e-fa5b724011f6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>There is a risk of QTc prolongation with overdosage. Intermittent hemodialysis is not likely to substantially remove BLUJEPA from the systemic circulation. Consider contacting the Poison Help line (1‑800‑222‑1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="ID_6e27a194-7ff6-4eea-9e88-0fbe2392b3d6">
               <id root="3f8db24d-b206-4e4e-b6ad-e53bf070c3ea"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>BLUJEPA tablets contain gepotidacin mesylate, a triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV. The chemical name is (<content styleCode="italics">R</content>)-2-((4-(((3,4-dihydro-2<content styleCode="italics">H</content>-pyrano[2,3-<content styleCode="italics">c</content>]pyridin-6-yl)methyl)amino)piperidin-1-yl)methyl)-1,2-dihydro-3<content styleCode="italics">H</content>,8<content styleCode="italics">H</content>-2a,5,8a-triazaacenaphthylene-3,8-dione methanesulfonate dihydrate. The molecular formula is C<sub>24</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub>●CH<sub>4</sub>O<sub>3</sub>S●2H<sub>2</sub>O and its molecular mass is 580.66. The structural formula is shown below.</paragraph>
                  <renderMultiMedia referencedObject="F02458B2-7640-4B6F-8392-7DC87A1E0C4A" ID="id666364922"/>
                  <paragraph>*stereogenic center</paragraph>
                  <paragraph>Each BLUJEPA oral tablet contains gepotidacin 750 mg (equivalent to 910.7 mg of gepotidacin mesylate [anhydrous]). Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="F02458B2-7640-4B6F-8392-7DC87A1E0C4A">
                     <text>Gepotidacin mesylate dihydrate chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="blujepa-spl-graphic-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f1ae2735-1ab7-467d-b2be-0b3465e24288">
               <id root="b95b02b2-a032-4d67-8fa0-1378e6db749f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="ID_a99d30a9-0742-42f3-929c-4d38943bd6e6">
                     <id root="f3d9c15f-fbcd-4ec5-8c3e-3ee7bfb66e27"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>BLUJEPA is an antibacterial drug <content styleCode="italics">[see Microbiology (<linkHtml href="#ID_58d4e44e-b099-473f-a52c-836addf2c3be">12.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_345d3108-5a4c-40a5-8e00-e8550675d5fc">
                     <id root="2020f408-c5f0-4edd-98ab-2aeae9e3e303"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The 24-hour free‑drug AUC to minimum inhibitory concentration (MIC) ratio has been shown in animal infection and in vitro pharmacokinetic ‑pharmacodynamic (PK‑PD) models to be the PK‑PD index predictive of gepotidacin antibacterial efficacy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>The effect of gepotidacin on the QTc interval was evaluated in a randomized, active (moxifloxacin 400 mg) and placebo‑controlled, double‑blind cross‑over trial in healthy subjects who received single intravenous (IV) infusions of gepotidacin over 2 hours. A dose- and concentration‑dependent QTc prolongation effect of gepotidacin was observed. The mean placebo‑corrected change from baseline heart rate values around T<sub>max</sub> were approximately 6 bpm at 1,000 mg IV (not an approved dosing regimen and route of administration) and approximately 10 bpm at 1,800 mg IV (not an approved dosing regimen and route of administration). The mean placebo‑corrected change from baseline QTcF values around T<sub>max</sub> were 12 msec at 1,000 mg IV and 22 msec at 1,800 mg IV <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>)]</content>. The C<sub>max</sub> of gepotidacin following a single 1,000 mg IV dose (not an approved dosing regimen and route of administration) is approximately 1.7 times that of the C<sub>max</sub> at steady state for the 1,500 mg oral dose twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">
                     <id root="6cb3c4b8-50bb-427d-a5c9-091f090a5af9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pharmacokinetic Parameters</content>
                        </paragraph>
                        <paragraph>The pharmacokinetic properties of gepotidacin are summarized in <linkHtml href="#_Ref192845721">Table 2</linkHtml> as mean (standard deviation [SD]) unless otherwise specified.</paragraph>
                        <table ID="_Ref192845721" width="100%">
                           <caption>Table 2. Pharmacokinetic Parameters of Gepotidacin</caption>
                           <col width="39%"/>
                           <col width="61%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="2">
                                    <sup>a </sup>Pharmacokinetic parameters are presented at steady state in patients with uUTI and eGFR greater than or equal to 90 mL/min after oral administration of BLUJEPA 1500 mg every 12 hours over 5 days.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="2">
                                    <sup>b </sup>Studies evaluating the effect on food were performed with standard and moderate fat meal. Clinical studies were not performed with a high fat meal (1000 calories, 50% fat).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>General Information</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Exposure</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Cmax (mcg/mL)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4.2 (1.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>AUC<sub>0-12 </sub>(mcg*hour/mL)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>22.8 (4.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Dose Proportionality</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Approximately dose proportional from 1,500 to 3,000 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Accumulation</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>40% and steady state was achieved by Day 3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Absorption</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Absolute Bioavailability</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>~45%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Tmax, (hours)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>~2.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Effect of food (moderate fat meal)<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>No clinically significant effect on PK</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Distribution</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Vss (L)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>172.9 (42.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Plasma Protein Binding</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>~25 to ~41%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Elimination</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Terminal Half-life (hours)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>9.3 (1.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Total Clearance (L/hour)<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>33.4 (6.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Primary Pathway</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Oxidative metabolism mediated by CYP3A4, producing several circulating metabolites</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Major Metabolite (%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>M4 which is ~11% of circulating drug-related materials</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>Feces</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>~52% (30% unchanged drug)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>Urine</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>~31% (20% unchanged drug; major route of elimination for absorbed gepotidacin)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>Modelling and simulation analyses of gepotidacin showed no clinically relevant effect of age (12 to &lt;18 years of age or 65 to 89 years of age), sex, race, or body weight (range: 40 kg to 140 kg) on gepotidacin exposure <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_9ba66cd4-ee13-4b5d-806b-6ecc2fa670d6">8.4</linkHtml>), (<linkHtml href="#ID_62dd13e6-a3df-44a4-9836-6dd76931b082">8.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment:</content> The pharmacokinetics of gepotidacin were evaluated in subjects with moderate renal impairment (eGFR 30 to 59 mL/min) and in subjects with severe renal impairment/end stage renal disease (ESRD) on intermittent hemodialysis and not on intermittent hemodialysis (eGFR &lt;30 mL/min). Gepotidacin plasma C<sub>max</sub> and AUC in subjects with moderate renal impairment were 1.2‑fold and 1.5‑fold higher than matched healthy controls, respectively. Gepotidacin plasma C<sub>max</sub> and AUC in severe renal impairment/ESRD not on intermittent hemodialysis were 1.7-fold and 2.1‑fold higher than matched healthy controls, respectively. Gepotidacin plasma C<sub>max</sub> and AUC in ESRD subjects requiring intermittent hemodialysis were 2.3‑fold and 2.5‑fold higher before intermittent hemodialysis than healthy matching subjects, respectively, and were 6.2‑fold and 4.2‑fold higher after intermittent hemodialysis than matched healthy controls, respectively <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_db5c9302-bc72-4e10-b354-f03daaef33ed">8.6</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment:</content> Moderate hepatic impairment did not have a clinically relevant effect on gepotidacin pharmacokinetics. In subjects with severe hepatic impairment compared with subjects with normal hepatic function, gepotidacin plasma exposure parameters (C<sub>max</sub> and AUC) were increased by approximately 1.9‑fold and 1.7‑fold, respectively <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_3f8d7286-61e4-480c-b336-753162a98f58">8.7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of CYP3A4 Inhibitors on the Pharmacokinetics of Gepotidacin</content>:</content> Concomitant administration of a strong inhibitor of CYP3A4 (itraconazole; 200 mg per day for 3 days), and a single 1,500 mg dose of BLUJEPA resulted in an increase in the maximum concentration (C<sub>max</sub>) of gepotidacin of approximately 1.4‑fold and area under the curve (AUC) of approximately 1.5‑fold <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_084554e9-1731-4e83-a89c-9a64e3908c96">7.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of CYP3A4 Inducers on the Pharmacokinetics of Gepotidacin</content>:</content> Concomitant administration of BLUJEPA (single 1,500 mg dose) with a strong CYP3A4 inducer (rifampin; 600 mg once daily for 7 days) resulted in a decrease of 52% in gepotidacin plasma AUC(0-∞) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_2654249c-224d-441b-bd81-76029c98c689">7.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of BLUJEPA on Pharmacokinetics of Other Drugs</content>:</content> Concomitant administration of a single 0.5 mg dose of digoxin with two 3,000 mg doses of BLUJEPA (an in vitro P‑glycoprotein inhibitor), given 12 hours apart (not an approved dosage of BLUJEPA), resulted in a 1.5‑fold increase in the digoxin C<sub>max</sub> (at 3 hours post dose), a 1.1‑fold increase in the digoxin AUC(0-∞), and a delayed digoxin T<sub>max</sub>
                           <content styleCode="italics"> [see Drug Interactions (<linkHtml href="#ID_2654249c-224d-441b-bd81-76029c98c689">7.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Concomitant administration of midazolam (2 mg single dose) with BLUJEPA (2 doses of 3,000 mg, given 12 hours apart; not an approved dosage of BLUJEPA) resulted in a 1.9‑fold increase in midazolam AUC(0-∞) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_2654249c-224d-441b-bd81-76029c98c689">7.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In-Vitro Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>In vitro, gepotidacin was not an inducer of CYP1A2, 2B6 or 3A4. In vitro<content styleCode="italics">,</content> gepotidacin is not a substrate of any of the hepatic organic anion transporting polypeptides (OATPs) 1B1, 1B3, and 2B1, organic anion transporters (OATs) OAT1, OAT2 and OAT3, organic cation transporters (OCTs) OCT2 and OCT3.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically</content>
                        </paragraph>
                        <paragraph>In vitro, gepotidacin inhibited multidrug and toxin extrusion (MATEs) MATE1 (IC<sub>50</sub>=16.6 µM), and MATE2‑K (IC<sub>50</sub>=6.9 μM). In vitro, gepotidacin is a substrate of breast cancer resistance protein (max flux rate ratio of 11.0).</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_58d4e44e-b099-473f-a52c-836addf2c3be">
                     <id root="e158ca5b-4830-4c61-a643-e62718727c88"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="49489-8" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>BLUJEPA is a triazaacenaphthylene antibacterial that inhibits Type II topoisomerases including bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, thereby inhibiting DNA replication.</paragraph>
                        <paragraph>Gepotidacin has bactericidal activity against pathogens as determined by time‑kill studies. In vitro studies demonstrated a gepotidacin post‑antibiotic effect ranging from 1.8 to 2.2 hours for <content styleCode="italics">E. coli</content>, 1 to &gt;6.6 hours for <content styleCode="italics">K. pneumoniae</content>, 1.4 to 3 hours for <content styleCode="italics">P. mirabilis</content>, 1 to 2.6 hours for <content styleCode="italics">C. freundii</content>, 2.7 to 4.3 hours for <content styleCode="italics">S. saprophyticus,</content> and 1.2 to 2.7 hours for <content styleCode="italics">E. faecalis</content> at 5 times the MIC.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>Although no clear mechanisms of resistance have been identified for gepotidacin, potential mechanisms that may impact gepotidacin activity are gepotidacin‑specific alterations of DNA gyrase (<content styleCode="italics">gyrA</content>, <content styleCode="italics">gyrB</content>) and/or topoisomerase IV (<content styleCode="italics">parC</content>, <content styleCode="italics">parE</content>) gene targets, plasmid‑mediated quinolone resistance genes (especially <content styleCode="italics">qnr</content>), and efflux. The following amino acids may be important for gepotidacin activity GyrA P35, V44, D82, A175, GyrB D426, P445 and ParC D79 as shown through studies with isogenic mutants in <content styleCode="italics">E. coli</content> and <content styleCode="italics">K. pneumoniae</content>. A single target‑specific mutation may not significantly impact gepotidacin activity. The relationship between gepotidacin and fluoroquinolone susceptibility does not appear to include amino acid substitutions in GyrA and ParC that are known to reduce fluoroquinolone susceptibility in <content styleCode="italics">E. coli</content>. Gepotidacin activity against <content styleCode="italics">E. coli</content> and <content styleCode="italics">K. pneumoniae</content> is unrelated to beta-lactam resistance mechanisms.</paragraph>
                        <paragraph>The frequency of resistance development to gepotidacin due to spontaneous mutations in the gram‑negative and gram‑positive uropathogens tested in vitro at 10 times MIC ranged from 10<sup>-9</sup> to 10<sup>-10</sup>.</paragraph>
                        <paragraph>Target‑specific cross‑resistance with other classes of antibacterial drugs has not been identified; therefore, isolates resistant to other drugs may be susceptible to gepotidacin. However, isolates of Enterobacterales with ≥4-fold increases in gepotidacin MIC have been identified in vitro and in clinical studies.</paragraph>
                        <paragraph>During clinical studies, gepotidacin demonstrated activity against some isolates of the following multilocus sequence typing (MLST) for <content styleCode="italics">E. coli</content>: ST10, ST131, ST1193, ST69, ST95 and ST73.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Interaction with Other Antimicrobials</content>
                        </paragraph>
                        <paragraph>In in vitro studies, no antagonism against Enterobacterales or gram‑positive isolates was observed for gepotidacin in combination with multiple antibacterial drugs, including fluoroquinolones, sulfonamides, cephalosporins, macrolides, tetracyclines, aminoglycosides, glycopeptides, carbapenems, nitrofurans, monobactams, and oxazolidinones.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Gepotidacin has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_ced5ab1e-5364-4f0d-970e-fc4296307f62">1</linkHtml>)]</content>:</paragraph>
                        <paragraph>Aerobic bacteria</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gram-positive bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Enterococcus faecalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Staphylococcus saprophyticus</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gram-negative bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Citrobacter freundii </content>complex</paragraph>
                        <paragraph>
                           <content styleCode="italics">     Escherichia coli</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Klebsiella pneumoniae</content>
                        </paragraph>
                        <paragraph>The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for gepotidacin against isolates of similar genus or organism group. However, the efficacy of gepotidacin in treating clinical infections caused by these bacteria has not been established in adequate and well‑controlled clinical trials.</paragraph>
                        <paragraph>Aerobic bacteria</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gram-negative bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Citrobacter koseri</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Klebsiella aerogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Klebsiella oxytoca/ Raoltella ornithinolytica</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Morganella morganii</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Proteus mirabilis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">     Providencia rettgeri</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Test Methods</content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5eec7c01-be05-4c49-88f9-493fd849c34e">
               <id root="a8a7ab8d-0191-4d2c-a5c4-412f9e93fc6f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="ID_0fa094a8-e5e3-491c-8873-c05215a7734a">
                     <id root="863dbeb7-2c53-4639-ad2b-5604b0d8c325"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long term carcinogenicity studies have not been conducted with gepotidacin.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Gepotidacin was positive in an in vitro micronucleus test in human peripheral blood lymphocytes and in an L5178Y mouse lymphoma assay, consistent with the known in vitro clastogenic effects of topoisomerase inhibitors in in vitro mammalian cell assays. Gepotidacin was negative in an in vivo micronucleus test or Comet assay in rat. Based on an overall weight of evidence, gepotidacin is unlikely to be genotoxic.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>In animal studies with gepotidacin, there were no adverse effects on fertility in male and female rats treated for approximately 3 weeks at 4-times the exposure at the MRHD (AUC extrapolated from rats orally administered the same dose for up to 4 weeks). There were no effects on spermatogenesis in rats and dogs at 4 and 5 times the exposure at MRHD, respectively, when treated for up to 13 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_294d4ebd-0091-4306-9e31-268af8fbc335">
               <id root="b26b0928-9f10-4fb9-92e5-7de71f0e4f79"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="ID_c5a40d9e-9aca-4203-ae71-14f99b2967e3">
                     <id root="5f3bb84b-8643-4eed-b435-290bd28bfc1f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Uncomplicated Urinary Tract Infections </title>
                     <text>
                        <paragraph>A total of 3,136 female patients with uUTI were randomized in 2 multicenter, parallel‑group, double‑blind, double‑dummy, non‑inferiority (NI) trials (Trial 1 [NCT04020341] and Trial 2 [NCT04187144]). Both trials compared BLUJEPA 1,500 mg (administered orally twice daily with food for 5 days) to nitrofurantoin 100 mg (administered orally twice daily for 5 days).</paragraph>
                        <paragraph>Patients entered the trials with at least 2 symptoms consistent with uUTI (dysuria, frequency, urgency, or lower abdominal pain) and with evidence of urinary nitrite or pyuria. Patients with any medical condition or presentation suggestive of a complicated UTI, or an upper UTI (e.g., pyelonephritis, urosepsis) were excluded.</paragraph>
                        <paragraph>Efficacy was assessed as a composite of clinical cure and microbiological response at the Test‑of‑Cure (TOC) Visit (Study Day 10 to 13) in the microbiological ITT nitrofurantoin‑susceptible (micro-ITTS) population, which included all patients who received at least 1 dose of study medication, had at least 1 baseline qualifying uropathogen (≥105 colony‑forming units [CFU]/mL), and excluded patients with organisms not susceptible to nitrofurantoin. Clinical cure was defined as resolution of all signs and symptoms of acute cystitis present at baseline and no new signs and symptoms without the patient receiving other systemic antimicrobials.</paragraph>
                        <paragraph>Microbiological response was defined as having all qualifying uropathogens found at baseline at ≥10<sup>5</sup> CFU/mL reduced to &lt;10<sup>3</sup> CFU/mL without the patient receiving other systemic antimicrobials.</paragraph>
                        <paragraph>Both trials demonstrated non‑inferiority of BLUJEPA to nitrofurantoin for composite response (<linkHtml href="#_Ref192845863">Table 3</linkHtml>).</paragraph>
                        <paragraph>In Trial 1, the micro-ITTS population consisted of 634 female patients with uUTI (n = 336 BLUJEPA; n = 298 nitrofurantoin). The median age of patients was 54 years, 57% were &gt;50 years of age, 84% were White, 40% had a history of recurrent infection. The U.S. enrolled the greatest percentage of patients (39%). Patient demographic and baseline characteristics were generally balanced between treatment groups <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>In Trial 2, the micro-ITTS population consisted of 567 female patients with uUTI (n = 292 BLUJEPA; n = 275 nitrofurantoin). The median age of patients was 51 years, 52% were &gt;50 years of age, 85% were White, 41% had history of recurrent infection. The majority of patients (67%) were enrolled from the U.S. Patient demographic and baseline characteristics were generally balanced between treatment groups<content styleCode="italics"> [see Adverse Reactions (<linkHtml href="#ID_1466cc64-2af5-4062-962b-af80d9e9d144">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <linkHtml href="#_Ref192845863">Table 3</linkHtml> summarizes the composite response, clinical cure, and microbiological response rates at the TOC visit for Trials 1 and 2 in the micro-ITTS population.</paragraph>
                        <table ID="_Ref192845863" width="100%">
                           <caption>Table 3. Composite Response, Clinical Cure, and Microbiological Response Rates at the Test-of-Cure Visit (Micro-ITTS Population)</caption>
                           <col width="27%"/>
                           <col width="24%"/>
                           <col width="23%"/>
                           <col width="26%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="4">Micro-ITTS = Microbiological Intent to Treat nitrofurantoin-susceptible; CI = confidence interval.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="4">
                                    <sup>a </sup>BLUJEPA was non-inferior to nitrofurantoin in both studies. The determination of Trial 1 non‑inferiority was based on a planned interim analysis of 607 subjects in Micro-ITTS population. The determination of Trial 2 non‑inferiority was based on a planned interim analysis of 541 subjects in Micro-ITTS population.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="4">
                                    <sup>b </sup>Treatment difference (BLUJEPA – nitrofurantoin) calculated using Miettinen and Nurminen Summary Score method adjusting for age group and recurrent/non-recurrent infection status combinations.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Study Endpoint</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">BLUJEPA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Nitrofurantoin</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Treatment Difference</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)<sup>b</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Trial 1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Composite response<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>174/336 (51.8)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>140/298 (47.0)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>5.3 (-2.4, 13.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Clinical cure</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>224/336 (66.7)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>196/298 (65.8)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>1.5 (-5.8, 8.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Microbiological response</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>244/336 (72.6)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>199/298 (66.8)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>6.0 (-1.2, 13.1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Trial 2</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Composite response<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>172/292 (58.9)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>121/275 (44.0)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>14.4 (6.4, 22.4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>Clinical cure</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>199/292 (68.2)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>175/275 (63.6)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4.3 (-3.4, 12.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>Microbiological response</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>213/292 (72.9)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>158/275 (57.5)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>15.5 (7.9, 23.1)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <linkHtml href="#_Ref192845897">Table 4</linkHtml> summarizes the composite response rates at the TOC Visit for the most common baseline uropathogens across both trials in the micro-ITTS population.</paragraph>
                        <table ID="_Ref192845897" width="100%">
                           <caption>Table 4. Composite Response Rates at the Test-of-Cure Visit by Baseline Uropathogen (Trial 1 and Trial 2 Pooled; Micro-ITTS Population)<sup>a</sup>
                           </caption>
                           <col width="32%"/>
                           <col width="35%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">Micro-ITTS = Microbiological Intent to Treat nitrofurantoin-susceptible;</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">
                                    <sup>a </sup>A patient is counted once under a uropathogen category if multiple qualifying uropathogens within that category are isolated at baseline for the patient.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="3">
                                    <sup>b </sup>Patients may have been infected with 1 to 2 uropathogens at baseline.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen<sup>b</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">BLUJEPA<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Nitrofurantoin<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Escherichia coli</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>312/566 (55.1)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>234/520 (45.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Klebsiella pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>6/14 (42.9)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>6/16 (37.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Citrobacter freundii </content>complex</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>8/12 (66.7)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>2/5 (40.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="italics">Staphylococcus saprophyticus</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>9/15 (60.0)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>11/14 (78.6)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="italics">Enterococcus faecalis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>8/14 (57.1)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>2/7 (28.6)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e04fe094-ff9f-4e1d-975b-bccaa0125134">
               <id root="4b0a9cd2-851d-46d2-b340-47fdd7416750"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>BLUJEPA tablets are supplied as yellow, film-coated, capsule-shaped tablets debossed with “GS GU3” on one side and plain on the other side, containing 750 mg of gepotidacin.</paragraph>
                  <paragraph>Bottle of 20 tablets (NDC 0173-0922-45).</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="ID_b17dd2f9-062b-4d03-b602-bf27fab85f99">
               <id root="4d069a81-1eff-493c-8b3c-51b7115f24c9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>Counsel patients to take BLUJEPA after a meal to reduce the possibility of gastrointestinal intolerance <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_8b94f772-a22d-433c-8535-699f0731f059">2.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Prolongation of the QTc Interval</content>
                  </paragraph>
                  <paragraph>Counsel patients to inform their healthcare provider of any personal or family history of QTc prolongation or proarrhythmic conditions such as hypokalemia, bradycardia, or recent myocardial ischemia, or if they are taking any antiarrhythmic agents. Advise patients to notify their healthcare providers if they have any symptoms of prolongation of the QTc interval, including prolonged heart palpitations or a loss of consciousness <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Acetylcholinesterase Inhibition</content>
                  </paragraph>
                  <paragraph>Counsel patients that BLUJEPA can cause dysarthria and other symptoms such as presyncope, muscle spasms, diarrhea, nausea, vomiting, abdominal pain, hypersalivation, and hyperhidrosis. Advise patients to inform their healthcare provider if they experience these symptoms or if they have an underlying medical condition that may be exacerbated by acetylcholinesterase inhibition or are planning to receive anesthesia where they may receive neuromuscular blocking agents, or if they are receiving other acetylcholinesterase inhibitors, or systemic anticholinergic medications <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ac8a806c-4ede-4931-a814-cc2f1790195d">5.2</linkHtml>), and Drug Interactions (<linkHtml href="#ID_86f6685b-3186-44a9-b7ea-70717dd0fa96">7.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that hypersensitivity reactions, including anaphylaxis, could occur and require immediate treatment. Advise patients to inform their healthcare provider about any previous hypersensitivity reactions to BLUJEPA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_5d00828f-b4fe-4da0-97de-23a789ad672f">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Potentially Serious Diarrhea</content>
                  </paragraph>
                  <paragraph>Counsel patients that diarrhea is a common problem caused by antibacterials, including BLUJEPA, and it usually ends when the antibacterial is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, patients should contact their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ad8b4566-6229-492b-b1e7-a66d456566ed">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance</content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs, including BLUJEPA, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When BLUJEPA is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by BLUJEPA or other antibacterial drugs in the future <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_04171f7f-dfc2-4fe3-9b2d-b1ff6bf0a92b">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients of the potential interactions other medications may have with BLUJEPA or the effect BLUJEPA may have on other medications, as these may result in decreased effectiveness or increased toxicities of either BLUJEPA or the other medications. Patients should alert their healthcare provider if they are currently taking any medications, including herbal nutritional supplements, or are prescribed new medications during treatment with BLUJEPA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ee8b85ac-6190-44aa-8b8a-8d6cf54ca754">5.1</linkHtml>), Drug Interactions (<linkHtml href="#ID_24072bad-2512-4604-b60d-ca5843457673">7</linkHtml>), and Clinical Pharmacology (<linkHtml href="#ID_70ce735c-3ff9-4968-b0b3-c26664029ee2">12.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise patients who are exposed to BLUJEPA during pregnancy to contact GlaxoSmithKline at 1‑888‑825‑5249 <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_6e972305-6fe3-41a2-982e-9aea127d17d6">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Manufactured for</paragraph>
                  <paragraph>GlaxoSmithKline<br/>Durham, NC 27701</paragraph>
                  <paragraph>©2025 GSK group of companies or its licensor.</paragraph>
                  <paragraph>BLJ:1PI</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="ID_c4e73ba7-b74a-4e94-8640-e30e03afd7bd">
               <id root="da7a655c-bdf8-4b5d-9df8-28f9e9a6a2eb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42231-1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%" cellpadding="5.75pt">
                     <col width="50%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">BLUJEPA (blu – JEP – ah)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(gepotidacin)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">tablets, for oral use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about BLUJEPA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">BLUJEPA, an antibiotic, can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">QTc prolongation.</content> BLUJEPA can cause QTc prolongation (also called prolonged QTc interval) that can lead to serious heart rhythm problems, including Torsade de Pointes. There may be changes in your heartbeat (a fast or irregular heartbeat).<br/>
                                    <content styleCode="bold">Before starting BLUJEPA, tell your healthcare provider if you:</content>
                                 </item>
                                 <item>
                                    <caption> </caption>○ or anyone in your family has ever had a heart rhythm problem (problem with heart rate or heartbeat) or QTc prolongation.</item>
                                 <item>
                                    <caption> </caption>○ are taking any medicines to treat heart rhythm problems. Using these medicines with BLUJEPA may cause serious side effects. If you are not sure, ask your healthcare provider.</item>
                              </list>
                              <paragraph>Tell your healthcare provider right away if you have any of the following symptoms:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ fast, pounding, or uneven heartbeat</item>
                                 <item>
                                    <caption> </caption>○ feeling dizzy</item>
                                 <item>
                                    <caption> </caption>○ you lose consciousness (pass out)</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ feeling lightheaded</item>
                                 <item>
                                    <caption> </caption>○ feeling faint</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">cholinergic effects.</content> BLUJEPA can cause an increase of a certain chemical in your nervous system, called acetylcholine. When acetylcholine is increased in your nervous system it may cause symptoms (cholinergic effects).</item>
                              </list>
                              <paragraph>The following symptoms may be caused by an increase in acetylcholine:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ diarrhea</item>
                                 <item>
                                    <caption> </caption>○ vomiting</item>
                                 <item>
                                    <caption> </caption>○ feeling faint</item>
                                 <item>
                                    <caption> </caption>○ trouble saying words clearly</item>
                                 <item>
                                    <caption> </caption>○ muscle spasms</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ nausea</item>
                                 <item>
                                    <caption> </caption>○ more saliva in the mouth</item>
                                 <item>
                                    <caption> </caption>○ more sweating</item>
                                 <item>
                                    <caption> </caption>○ stomach pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>Call your healthcare provider right away if you have trouble saying words clearly, have shortness of breath, or if you faint. These symptoms may be cholinergic effects of BLUJEPA.</paragraph>
                              <paragraph>Increased acetylcholine can also be connected to other symptoms. Call your healthcare provider right away if you have any of these additional symptoms.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ irregular heartbeat (heart block)</item>
                                 <item>
                                    <caption> </caption>○ slow heartbeat (bradycardia)</item>
                                 <item>
                                    <caption> </caption>○ seizures</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ fainting</item>
                                 <item>
                                    <caption> </caption>○ chest tightness causing difficulty breathing</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">allergic reactions. </content>Allergic reactions can happen in people who take BLUJEPA including a severe allergic reaction called anaphylaxis. Stop taking BLUJEPA and get medical help right away if you have any symptoms of a severe allergic reaction, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ hives</item>
                                 <item>
                                    <caption> </caption>○ feeling faint or dizzy</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ rash</item>
                                 <item>
                                    <caption> </caption>○ swelling of your lips, tongue, or throat</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">diarrhea.</content> Diarrhea is a common side effect caused by antibiotics including BLUJEPA. The diarrhea usually stops after the antibiotic is stopped. In some cases, diarrhea may be caused by <content styleCode="italics">Clostridioides difficile infection </content>(CDI). CDI is a severe infection of the intestines (bowels) that can happen up to 2 months after finishing treatment with antibiotic medicines, including BLUJEPA. CDI can be life-threatening and can lead to death. Do not take medicines to treat diarrhea without checking first with your healthcare provider. Call your healthcare provider right away if you have the following symptoms:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ stomach cramps</item>
                                 <item>
                                    <caption> </caption>○ fever</item>
                                 <item>
                                    <caption> </caption>○ watery diarrhea</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule Botrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ diarrhea that does not go away</item>
                                 <item>
                                    <caption> </caption>○ bloody stools</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">What is BLUJEPA?</content>
                              </paragraph>
                              <paragraph>BLUJEPA is an antibiotic used to treat women and girls 12 years of age and older weighing at least 88 pounds who have an infection of the bladder (known as an uncomplicated urinary tract infection [uUTI]) caused by certain types of bacteria.</paragraph>
                              <paragraph>It is not known if BLUJEPA is safe and effective in children under 12 years of age or weighing less than 88 pounds.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Do not take BLUJEPA if:</content>
                              </paragraph>
                              <paragraph>you have had a severe allergic reaction to BLUJEPA. See the end of this Medication Guide for a complete list of ingredients in BLUJEPA.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Before taking BLUJEPA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have heart rhythm problems. <content styleCode="bold">See “What is the most important information I should know about BLUJEPA?”</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>have a slow heartbeat (bradycardia).</item>
                                 <item>
                                    <caption>•</caption>have recently had a heart attack.</item>
                                 <item>
                                    <caption>•</caption>have low potassium in your blood (hypokalemia).</item>
                                 <item>
                                    <caption>•</caption>are planning to have a medical or surgical procedure that puts you to sleep (general anesthesia) that will use a type of medicine given through your veins (I.V.) that relaxes your muscles.</item>
                                 <item>
                                    <caption>•</caption>have liver problems.</item>
                                 <item>
                                    <caption>•</caption>have kidney problems, kidney failure, or are on dialysis.</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if BLUJEPA will harm your unborn baby.</item>
                              </list>
                              <paragraph>Tell your healthcare provider if you become pregnant or think you are pregnant during your treatment with BLUJEPA.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Pregnancy Exposure Registry:</content> There is a pregnancy exposure registry for women who are exposed to BLUJEPA during pregnancy. The purpose of this registry is to check the health of you and your baby. If you are pregnant or become pregnant during your treatment with BLUJEPA, talk to your healthcare provider about registering with GlaxoSmithKline. You can register by calling GlaxoSmithKline at 1‑888‑825‑5249.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if BLUJEPA passes into breast milk. Talk to your healthcare provider about the best way to feed your baby during your treatment with BLUJEPA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. BLUJEPA and other medicines may affect each other causing side effects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take</content> medicines to treat heart rhythm problems.</paragraph>
                              <paragraph>Ask your healthcare provider or pharmacist, if you are not sure if you are taking any of these medicines. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">How should I take BLUJEPA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Take BLUJEPA exactly as your healthcare provider tells you to take it. Check with your healthcare provider if you are not sure.</item>
                                 <item>
                                    <caption>•</caption>Take two tablets of BLUJEPA by mouth, 2 times each day (about 12 hours apart), for 5 days.</item>
                                 <item>
                                    <caption>•</caption>Take BLUJEPA after a meal to decrease the chance of stomach upset.</item>
                                 <item>
                                    <caption>•</caption>If you miss a dose, take it as soon as possible, then continue your treatment as before. Do not take 2 doses to make up for a missed dose.</item>
                                 <item>
                                    <caption>•</caption>If you take too much BLUJEPA, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                                 <item>
                                    <caption>•</caption>Take the full course of treatment with BLUJEPA. Do not stop taking BLUJEPA during your treatment unless your healthcare provider tells you to, even if you are feeling better. If you do not complete your full course of treatment, the infection may come back.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule ">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of BLUJEPA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">BLUJEPA can cause serious side effects including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">See the “What is the most important information I should know about BLUJEPA?”</content>
                                 </item>
                              </list>
                              <paragraph>The most common side effects of BLUJEPA include:</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ diarrhea</item>
                                 <item>
                                    <caption> </caption>○ nausea</item>
                                 <item>
                                    <caption> </caption>○ stomach pain</item>
                                 <item>
                                    <caption> </caption>○ gas</item>
                                 <item>
                                    <caption> </caption>○ headache</item>
                              </list>
                           </td>
                           <td valign="top" styleCode="Rrule ">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○ soft stools</item>
                                 <item>
                                    <caption> </caption>○ dizziness</item>
                                 <item>
                                    <caption> </caption>○ vomiting</item>
                                 <item>
                                    <caption> </caption>○ yeast infections</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>These are not all the possible side effects of BLUJEPA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">How should I store BLUJEPA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store BLUJEPA tablets at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep BLUJEPA and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of BLUJEPA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BLUJEPA for a condition for which it was not prescribed. Do not give BLUJEPA to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information about BLUJEPA that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in BLUJEPA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient: </content>gepotidacin mesylate</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide and yellow iron oxide.<br/>
                                 <br/>
                              </paragraph>
                              <paragraph>Manufactured for:</paragraph>
                              <paragraph>GlaxoSmithKline, Durham, NC 27701</paragraph>
                              <paragraph>©2025 GSK group of companies or its licensor.</paragraph>
                              <paragraph>BLJ:1MG</paragraph>
                              <paragraph>For more information, call 1-888-825-5249 or go to www.gsk.com.</paragraph>
                              <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.                       Revised: March 2025</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="ID_3b5003fc-4186-4223-9a61-a9b6548013d4">
               <id root="bb75d106-c293-44cc-9901-1e62ceff9ce6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCICPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0922-45</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">BLUJEPA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(gepotidacin)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">750 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20</content> tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>Each tablet contains 750 mg of gepotidacin (equivalent to 910.7 mg of gepotidacin mesylate [anhydrous]).</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Keep out of reach of children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is missing or broken.</content>
                  </paragraph>
                  <paragraph>Trademarks owned or licensed by GSK.</paragraph>
                  <paragraph>Mft. For: GSK, Durham, NC 27701</paragraph>
                  <paragraph>Scan for product information or visit epi-pla.org</paragraph>
                  <paragraph>Made in Belgium</paragraph>
                  <paragraph>©2025 GSK or licensor. Rev. 03/23</paragraph>
                  <paragraph>2000017942</paragraph>
                  <renderMultiMedia referencedObject="ID_52faecdd-e2e4-4788-bd46-196fd882d953" ID="id921839221"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="ID_52faecdd-e2e4-4788-bd46-196fd882d953">
                     <text>Blujepa tablet 20 count label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="blujepa-spl-graphic-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>